Common use of Minimum Royalty Rate Clause in Contracts

Minimum Royalty Rate. Anything contained in this Agreement to the contrary notwithstanding, none of the reductions to royalties provided in Sections 5.3(b), 5.3(c) and 5.3(d) hereof, shall, individually or in the aggregate, [***] the royalties payable with respect to Net Sales of any Licensed Product sold by Lilly, its Affiliates and its Sublicensees in any country during the Royalty Term by more than [***] of the royalties otherwise owed to ImmunoGen pursuant to Section 5.3(a) or 5.3(e), as applicable, without giving effect to any royalty reduction provided in Section 5.3(b), 5.3(c) or 5.3(d) hereof.

Minimum Royalty Rate. Anything contained in this Agreement to the contrary notwithstanding, none of the reductions to royalties provided in Sections 5.3(b4.2.3(a), 5.3(c4.2.3(b) and 5.3(d4.2.3(c) hereof, shall, individually or in the aggregate, [***] the royalties payable with respect to Net Sales of any Licensed Product sold by LillyImmunoGen, its Affiliates and its Sublicensees in any country during the Royalty Term by more than [***] of the royalties otherwise owed to ImmunoGen CytomX pursuant to Section 5.3(a) 4.2.1 or 5.3(e4.2.3(d), as applicable, without giving effect to any royalty reduction provided in Section 5.3(b4.2.3(a), 5.3(c4.2.3(b) or 5.3(d4.2.3(c) hereof.

Minimum Royalty Rate. Anything contained in this Agreement to the contrary notwithstanding, none of the reductions to royalties provided in Sections 5.3(b4.2.3(a), 5.3(c4.2.3(b) and 5.3(d4.2.3(c) hereof, shall, individually or in the aggregate, [***] the royalties payable with respect to Net Sales of any Licensed Product sold by LillyCytomX, its Affiliates and its Sublicensees in any country during the Royalty Term by more than [***] of the royalties otherwise owed to ImmunoGen pursuant to Section 5.3(a) 4.2.1 or 5.3(e4.2.3(d), as applicable, without giving effect to any royalty reduction provided in Section 5.3(b4.2.3(a), 5.3(c4.2.3(b) or 5.3(d4.2.3(c) hereof.

Minimum Royalty Rate. Anything contained in this Agreement to the contrary notwithstanding, none of the reductions to royalties provided in Sections 5.3(b4.2.3(a), 5.3(c4.2.3(b) and 5.3(d4.2.3(c) hereof, shall, individually or in the aggregate, [***] reduce the royalties payable with respect to Net Sales of any Licensed Product sold by LillyCytomX, its Affiliates and its Sublicensees in any country during the Royalty Term by more than [***] fifty percent (50%) of the royalties otherwise owed to ImmunoGen pursuant to Section 5.3(a) 4,2.1 or 5.3(e4.2.3(d), as applicable, without giving effect to any royalty reduction provided in Section 5.3(b4.2.3(a), 5.3(c4.2.3(b) or 5.3(d4.2.3(c) hereof.

Minimum Royalty Rate. Anything contained in this Agreement to the contrary notwithstanding, none of the reductions to royalties provided in Sections 5.3(b4.2.3(a), 5.3(c4.2.3(b) and 5.3(d4.2.3(c) hereof, shall, individually or in the aggregate, [***] reduce the royalties payable with respect to Net Sales of any Licensed Product sold by LillyCytomX, its Affiliates and its Sublicensees in any country during the Royalty Term by more than [***] of the royalties otherwise owed to ImmunoGen pursuant to Section 5.3(a) 4.2.1 or 5.3(e4.2.3(d), as applicable, without giving effect to any royalty reduction provided in Section 5.3(b4.2.3(a), 5.3(c4.2.3(b) or 5.3(d4.2.3(c) hereof. ***Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Minimum Royalty Rate. Anything contained in this Agreement to the contrary notwithstanding, none of the reductions to royalties provided in Sections 5.3(b4.2.3(a), 5.3(c4.2.3(b) and 5.3(d4.2.3(c) hereof, shall, individually or in the aggregate, [***] reduce the royalties payable with respect to Net Sales of any Licensed Product sold by LillyCytomX, its Affiliates and its Sublicensees in any country during the Royalty Term by more than [***] fifty percent (50%) of the royalties otherwise owed to ImmunoGen pursuant to Section 5.3(a) 4.2.1 or 5.3(e4.2.3(d), as applicable, without giving effect to any royalty reduction provided in Section 5.3(b4.2.3(a), 5.3(c4.2.3(b) or 5.3(d4.2.3(c) hereof.

Minimum Royalty Rate. Anything contained in this Agreement to the contrary notwithstanding, none of the reductions to royalties provided in Sections 5.3(b4.2.3(a), 5.3(c4.2.3(b) and 5.3(d4.2.3(c) hereof, shall, individually or in the aggregate, [***] reduce the royalties payable with respect to Net Sales of any Licensed Product sold by LillyImmunoGen, its Affiliates and its Sublicensees in any country during the Royalty Term by more than [***] fifty percent (50%) of the royalties otherwise owed to ImmunoGen CytomX pursuant to Section 5.3(a) 4.2.1 or 5.3(e4.2.3(d), as applicable, without giving effect to any royalty reduction provided in Section 5.3(b4.2.3(a), 5.3(c4.2.3(b) or 5.3(d4.2.3(c) hereof.

Minimum Royalty Rate. Anything contained in this Agreement to the contrary notwithstanding, none of the reductions to royalties provided in Sections 5.3(b4.2.3(a), 5.3(c4.2.3(b) and 5.3(d4.2.3(c) hereof, shall, individually or in the aggregate, [***] reduce the royalties payable with respect to Net Sales of any Licensed Product sold by LillyImmunoGen, its Affiliates and its Sublicensees in any country during the Royalty Term by more than [***] of the royalties otherwise owed to ImmunoGen CytomX pursuant to Section 5.3(a) 4.2.1 or 5.3(e4.2.3(d), as applicable, without giving effect to any royalty reduction provided in Section 5.3(b4.2.3(a), 5.3(c4.2.3(b) or 5.3(d4.2.3(c) hereof.